# Jubilant Pharmova (NSE: JUBLPHARMA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/JUBLPHARMA · Pivot · prices to 22 Oct 2026

Jubilant Pharmova (NSE: JUBLPHARMA) closed at ₹930.80 on 22 Oct 2026, down 0.02% on the day. With a market capitalisation of ₹14,848 Cr, it ranks 427th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 37.1× trailing earnings, against a return on equity of 13.4% in FY25. Over the past year the share price has fallen 13.4%. Its 52-week range is ₹786.05 (9 Mar 2026) to ₹1,183.00 (4 Nov 2025); the last close is 21.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹2,272 Cr (+18.6% year on year) and net profit ₹119 Cr (−21.2%), on a consolidated basis. Promoters held 47.68% of the company as of 30 Jun 2026; 6.58% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹930.80 |
| Market cap | ₹14,848 Cr |
| P/E (trailing) | 37.1 |
| ROE | 13.4% (FY25) |
| ROCE | 8.1% (FY25) |
| Debt to equity | 0.39 |
| 52-week high | ₹1,183.00 (4 Nov 2025) |
| 52-week low | ₹786.05 (9 Mar 2026) |
| 1-year return | −13.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹2,272 Cr | +18.6% | ₹119 Cr | −21.2% | ₹7.55 |
| Q3 FY26 | ₹2,116 Cr | +16.7% | ₹56 Cr | −44.7% | ₹3.52 |
| Q2 FY26 | ₹1,958 Cr | +11.7% | ₹120 Cr | +17.0% | ₹7.59 |
| Q1 FY26 | ₹1,879 Cr | +9.2% | ₹103 Cr | −78.7% | ₹6.49 |
| Q4 FY25 | ₹1,916 Cr | +9.7% | ₹151 Cr | — | ₹9.71 |
| Q3 FY25 | ₹1,814 Cr | +8.9% | ₹101 Cr | +89.5% | ₹6.37 |
| Q2 FY25 | ₹1,752 Cr | +5.1% | ₹103 Cr | +93.2% | ₹6.47 |
| Q1 FY25 | ₹1,720 Cr | +9.8% | ₹482 Cr | +6,410.8% | ₹30.44 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹7,235 Cr | ₹837 Cr |
| FY24 | ₹6,703 Cr | ₹49 Cr |
| FY23 | ₹6,282 Cr | −₹77 Cr |
| FY22 | ₹6,130 Cr | ₹423 Cr |
| FY21 | ₹6,099 Cr | ₹824 Cr |
| FY20 | ₹5,976 Cr | ₹898 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 47.68%
- Foreign institutions: 15.87%
- Domestic institutions: 12.40%
- Non-institutions: 23.50%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,143.60 | ₹15,537 Cr | 25.3 | 15.9% |
| [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹785.00 | ₹15,357 Cr | 22.9 | 11.2% |
| [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,056.00 | ₹15,252 Cr | 80.9 | 15.0% |
| [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹370.75 | ₹15,037 Cr | 47 | 6.5% |
| [Dr. Agarwal's Health Care](https://app.pivotnow.in/stock/AGARWALEYE) | ₹459.10 | ₹14,852 Cr | 100 | 6.6% |
| [Poly Medicure](https://app.pivotnow.in/stock/POLYMED) | ₹1,479.10 | ₹14,686 Cr | 46.7 | 10.4% |

## Questions and answers

### What is the share price of Jubilant Pharmova today?

Jubilant Pharmova (NSE: JUBLPHARMA) last closed at ₹930.80 on 22 Oct 2026. Its 52-week high is ₹1,183.00 and its 52-week low is ₹786.05.

### What is the market cap of Jubilant Pharmova?

Jubilant Pharmova's market capitalisation is ₹14,848 Cr (₹14,848 Cr) at the 22 Oct 2026 close, ranking 427th among the NSE companies Pivot tracks.

### What is the P/E ratio of Jubilant Pharmova?

Jubilant Pharmova trades at a trailing P/E of 37.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 47.

### What is the ROE and ROCE of Jubilant Pharmova?

Return on equity was 13.4% in FY25 and return on capital employed was 8.1% in FY25 (consolidated figures).

### Is Jubilant Pharmova a debt-free company?

No. Jubilant Pharmova's debt-to-equity ratio was 0.39 in FY25, with total debt of ₹2,150 Cr.

### What were Jubilant Pharmova's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Jubilant Pharmova reported revenue of ₹2,272 Cr, +18.6% year on year, and net profit of ₹119 Cr, −21.2% year on year.

### How has Jubilant Pharmova stock performed over the last year?

Jubilant Pharmova's share price has fallen 13.4% over the past year, −6.6% over three months and −11.2% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Jubilant Pharmova?

As of 30 Jun 2026: promoters 47.68%, foreign institutions 15.87%, domestic institutions 12.40%, non-institutions 23.50%. 6.58% of promoter shares were pledged.

### Who are Jubilant Pharmova's competitors?

The listed Pharma & Healthcare companies closest to Jubilant Pharmova by market cap are Eris Lifesciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Syngene International, Dr. Agarwal's Health Care and Poly Medicure.

### Is Jubilant Pharmova a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Jubilant Pharmova's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JUBLPHARMA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.